AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein...
NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases
March 08, 2023 13:27 ET
|
NKGen Biotech
SANTA ANA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
March 06, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 07, 2023 07:00 ET
|
AC Immune SA
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer...
IGC Announces Updated Life Sciences Presentation
December 20, 2022 08:30 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with...
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
November 23, 2022 07:30 ET
|
AC Immune SA
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and...
Genomic transposable elements modify the progression of Parkinson's disease
November 08, 2022 10:00 ET
|
Experimental Biology and Medicine
WASHINGTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 18, September, 2022) improves our understanding of genomic...
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease
November 04, 2022 12:35 ET
|
NKGen Biotech
SANTA ANA, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell...
Datavant and Parkinson’s Foundation Collaborate to Drive Insights into Parkinson’s Disease Research
July 19, 2022 08:00 ET
|
Datavant
NEW YORK and SAN FRANCISCO, July 19, 2022 (GLOBE NEWSWIRE) -- Datavant, the leader in helping organizations securely connect health data, and the Parkinson’s Foundation, a national nonprofit...
Study Identifies New DNA Clues for Parkinson's Disease Risk
June 15, 2022 10:00 ET
|
Experimental Biology and Medicine
WASHINGTON, June 15, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 11, June, 2022) identifies a potential transcriptional profile to...